Japan Agency Seeks To Take iPS Discoveries To Development
This article was originally published in PharmAsia News
Executive Summary
Japan's Science & Technology Agency holds the key for some researchers for developing new drugs based on artificial creation of human induced pluripotent stem cells. University researchers in Japan announced eight months ago they had created the iPS cells, but they have no way to get their knowledge to the phase of actually making new drugs and therapy. The JST is attempting to fill the gap with its cell-reprogramming project aimed at fostering the new science. (Click here for more - a subscription may be required
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.